To determine the minimum amount of Cupressus arizonica allergen extract producing a positive skin reactio

• Conditions: Allergy to Cupressus arizonica; MedDRA version: 17.1Level: LLTClassification code 10036019Term: Pollen allergySystem Organ Class: 100000004870; Therapeutic area: Diseases [C] - Immune System Diseases [C20]

• Registration Number: EUCTR2013-001309-98-ES
• Lead Sponsor: ABORATORIOS LETI, S.L.Unipersonal

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-02-27
• Last Update Posted: 8 February 2016

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Subject has provided written informed consent, appropriately signed and dated by subject.
Subject can be male or female of any race and ethinic group.
Age ? 18 years and ? 60 years ata the study inclusión day.
Positive clinical history of inhalatory allergy to Cupressus arizonica.
A positive prick test with a standarices commercially Cupressus arizonica allergen extract.
A positive prick test with positive control of histamine 10 mg/ml.
A positive test for specific IgE to Cupressus arizonica.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 30
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Immunotherapy in the past 5 years with an allergen extract Cupressus arizonca or other allergen extract tan may interfere with the allergene to be tested.
Use of drugs that may interfere before and after with the skin reactions.
Treatment with certain drugs.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified